Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Multiple Myeloma 130Recurrence 34Lymphoma, Follicular 28Lymphoma, Large B-Cell, Diffuse 27Lymphoma, Non-Hodgkin 23Neoplasms 13Lymphoma 13Lymphoma, Mantle-Cell 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Lymphocytic, Chronic, B-Cell 11Hematologic Diseases 5Neoplasms, Plasma Cell 4Myelodysplastic Syndromes 4Lymphoma, B-Cell 4Hematologic Neoplasms 4Neoplasm Metastasis 3Melanoma 3Leukemia, Myeloid, Acute 3Pyloric Stenosis, Hypertrophic 2Prostatic Neoplasms 2Paraproteinemias 2Ovarian Neoplasms 2Lymphoproliferative Disorders 2Lymphoma, T-Cell, Peripheral 2Leukemia-Lymphoma, Adult T-Cell 2Leukemia, B-Cell 2Leukemia 2Immunoproliferative Disorders 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2

Interventions

pembrolizumab 166Nivolumab 111Ipilimumab 93Dacarbazine 44trametinib 36dabrafenib 34Vemurafenib 33binimetinib 23atezolizumab 23Temozolomide 21cemiplimab 18Paclitaxel 18encorafenib 17spartalizumab 16cobimetinib 15Carboplatin 14talimogene laherparepvec 13Cisplatin 13Cyclophosphamide 11lenvatinib 10Pemetrexed 10Gemcitabine 10Docetaxel 10durvalumab 9Drug Therapy 9Bevacizumab 9tremelimumab 8Injections 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Melanoma × Lenalidomide × Clear all
NCT00057616 2019-11-08

Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

Celgene

Phase 3 Completed
274 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00179608 2019-11-08

Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy

Celgene

Phase 1 Completed
28 enrolled
Dermatologic

Melanoma

NCT00055562 2005-06-24

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Celgene

Phase 2/3 Completed
274 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡